Early Breast Cancer in the Elderly: Characteristics, Therapy, and Long-Term Outcome [0.03%]
老年早期乳腺癌的临床特征、治疗及长期预后
Omer Gal,Yael Ishai,Aaron Sulkes et al.
Omer Gal et al.
Objective: The number of older adults diagnosed with breast cancer is increasing. However, data on breast cancer characteristics, treatment, and survival in elderly women are sparse. ...
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience [0.03%]
单中心短输注曲贝替丁治疗多线卵巢癌患者的经验报告
Claudia Marchetti,Angela Musella,Alessia Romito et al.
Claudia Marchetti et al.
Objective: The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. ...
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study [0.03%]
卡培他滨、伊立替康、吉西他滨和贝伐单抗作为二线治疗药物治疗晚期胆道癌的疗效与安全性：一项II期临床研究
Finn Ole Larsen,Alice Markussen,Laura V Diness et al.
Finn Ole Larsen et al.
Objective: Since 2010, gemcitabine and cisplatin have been considered standard first-line treatment in patients with advanced biliary tract cancer. Many centers have replaced cisplatin with oxaliplatin, which seems to obt...
Clinical Trial
Oncology. 2018;94(1):19-24. DOI:10.1159/000479970 2018
Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints [0.03%]
基于一致的时间到事件终点的肛管癌确定性化学放射治疗的长期结果研究
Francesca De Felice,Maria Teresa Martinetti,Simone Orelli et al.
Francesca De Felice et al.
Aim: To report the long-term results after definitive chemoradiotherapy (CRT) for anal carcinoma, using consistent time-to-event endpoints. Methods and ma...
Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma [0.03%]
系统性炎性反应是人类免疫缺陷病毒阳性肝细胞癌患者的预后标志物
David J Pinato,Marco Merli,Alessia Dalla Pria et al.
David J Pinato et al.
Background: Hepatocellular carcinoma (HCC) is increasingly prevalent in people living with HIV. Systemic inflammation is a prognostic factor requiring validation in HIV-associated HCC. ...
Multicenter Study
Oncology. 2017;93(6):395-400. DOI:10.1159/000479521 2017
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma [0.03%]
胃癌中程序性死亡配体1和人表皮生长因子受体2的蛋白表达
Eiji Oki,Shinji Okano,Hiroshi Saeki et al.
Eiji Oki et al.
Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gast...
Buccal Epithelium, Cigarette Smoking, and Lung Cancer: Review of the Literature [0.03%]
颊黏膜上皮、吸烟与肺癌：文献综述
Raya Saba,Oleksandr Halytskyy,Nasir Saleem et al.
Raya Saba et al.
Lung cancer is currently the leading cause of cancer-related mortality among men and women in the United States, and optimal screening methods are still lacking. The field effect is a well-supported phenomenon wherein a noxious stimulus tri...
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions [0.03%]
可切除胃癌或胃食管结合部癌的新辅助卡培他滨、奥沙利铂和伊立替康治疗：病理学缓解为主要终点及FDG-PET预测指标
Rosa Berenato,Federica Morano,Filippo Pietrantonio et al.
Rosa Berenato et al.
Objectives: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal ...
Clinical Trial
Oncology. 2017;93(5):279-286. DOI:10.1159/000479154 2017
Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer [0.03%]
口服多靶点激酶抑制剂regorafenib治疗转移性结直肠癌的疗效和安全性分析
Giuseppe Cicero,Rossella De Luca,Francesco Dieli
Giuseppe Cicero
Background/aim: A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [García-Alfonso et al.: J Clin Transl On...
A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma [0.03%]
一项关于复发侵袭性高危淋巴瘤患者的Ⅱ期探索性研究：PXD-101（贝利司他）继帕博利珠单抗后用于治疗疗效及安全性的研究
Soham D Puvvada,José M Guillén-Rodríguez,Xavier I Rivera et al.
Soham D Puvvada et al.
Objective: Aggressive lymphomas (aNHL) including diffuse large B-cell lymphoma (DLBCL) have poor outcomes in relapsed refractory patients. Prior studies have demonstrated that loss of major histocompatibility complex clas...
Clinical Trial
Oncology. 2017;93(6):401-405. DOI:10.1159/000479230 2017